Wyeth To Launch Vaccine Against Meningitis

Image
Gauri Kamath BSCAL
Last Updated : Sep 22 1998 | 12:00 AM IST

Wyeth Lederle India will be adding an anti-meningitis vaccine to its drugs' portfolio. The vaccine, expected to be launched in a month, will combat HIB meningitis.

"The vaccine is a leading product abroad and is on the national health programme of most countries," said Baldev Arora, president and managing director of the company.

Last year, the company had launched Hibtitter, a vaccine for HIB meningitis in India for children under the age of five.

Also Read

The new vaccine, too, will be in the range of paediatrics. However, Arora did not disclose what the new vaccine would be called or how, if at all, it would be different from Hibtitter.

The company had said in its annual report that `the sales of Hibtitter have shown satisfactory growth in the current year'.

It is likely that encouraged by the sales the company is expanding its product range in the same category.

Hib meningitis is caused by the haemophilius influenza type-B bacteria. Struck by the disease, a person can suffer from pneumonia and serious joints infection. It can also lead to lasting brain damage.

Wyeth Lederle is involved in the manufacture of bulk drugs or intermediates as well as formulations.

It operates in the categories of female health care, steroids, antibiotics, central nervous system products and vaccines.

The company underwent a product rationalisation exercise last year where older products were discontinued. However, when questioned about a further restructuring of product portfolio, Arora said that he expected that question to be raised and answered at the company's forthcoming annual general meeting.

In 1997-98, domestic pharmaceutical sales showed a growth of 5.4 per cent but exports fell 35 per cent.

The company earned a total income of Rs 213.71 crore and a net profit of Rs 23.51 crore as compared with an income of Rs 168.61 crore and a net profits of Rs 15.51 crore in the previous year. Wyeth Lederle India has been formed by the merger of Cynamid India, John Wyeth India, Wyeth Laboratories and Wyeth India.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 22 1998 | 12:00 AM IST

Next Story